Botox Alternative May Safely Smooth Forehead Lines

Related Encyclopedia • Amenorrhea • Amniocentesis • Amniocentesis and CVS • Anovulation More... Related Healthscout Videos Incision-Free Bladder Surgery Tracking Breast Cancer with Less Pain 5 Breast Cancer Myths Software Makes Childbirth Safer More... Related Animations • Breast Reduction • Breast Self-Exam Video • Erectile Dysfunction • Facelift More... Related Drug Information • Actonel • Detrol LA • Diflucan • Ditropan XL More... Related News Articles • Bans on Same-Sex Marriage May Affect Mental Health • Certain Bone Drugs May Lower Breast Cancer Risk • Treating Gum Disease May Thwart Preterm Births • Freezing Technique May Stop Breast Cancer More...

Page:  << Prev | 1 | 2 | 3 | Next >>

"Reloxin is as safe and it works as well as Botox," said lead researcher Dr. Ronald Moy from the Moy-Fincher Medical Group in Los Angeles. "Many of our patients are happier and got a more natural look with the use of Reloxin."

"I think this will be as popular as Botox, which is the most common cosmetic procedure in the United States," Moy added.

But not all plastic surgeons are as enthusiastic, with some citing a heightened incidence of drooping of the eyelid and/or brow with Reloxin vs. Botox. "With this study, I don't see a clear advantage over Botox," said Dr. Jeffrey C. Salomon, an assistant clinical professor of plastic surgery at Yale University School of Medicine.

Text Continues Below

---

The report, which was funded by the drug's maker, Medicis Pharmaceutical Corp., is published in the March/April issue of the Archives of Facial Plastic Surgery.

For the study, Moy's team treated 1,200 patients with injections of Reloxin (Clostridium botulinum toxin type A-hemagglutinin complex) in five sites in the forehead. Patients kept diaries of the effects of the treatment and were surveyed a week to 10 days after treatment. In addition, patients were reexamined two weeks and 30 days later, and then each month after treatment.

Among the 1,052 patients who completed the 13-month study there were 2,838 adverse events among 880 patients. Of these, 28 percent were probably related to the treatment. These included problems at the injection site, nervous system disorders such as headache and eye problems including ptosis, a drooping of the eyelid or brow. Only one patient withdrew from study due to the side effects of the drug, the researchers say.

Patients reported that the drug started working within a day after treatment. After a week, as many as 95 percent of the patients reported showing a response to the medication. At 30 days after treatment, as many as 91 percent of the patients had a response, according to the researcher's assessment.

Page:  << Prev | 1 | 2 | 3 | Next >>